Reneo Pharmaceuticals Inc. (RPHM): Price-to-Sales Ratio

Corporate company logo of Reneo Pharma (RPHM)

The corporate structure of Reneo Pharmaceuticals (RPHM) is currently being systematically liquidated following a failed clinical trial. On GURU.Markets, the P/S multiple trend clearly demonstrates this dynamics, where the level reflects the current revenue valuation. The search for new licensed assets is stimulating growth, while independence from macroeconomic factors makes this defensive sector a reliable tool for investors.

RPHM: Reneo Pharmaceuticals P/S Multiple 07/04/2022 - 11/14/2026

Metric breakdowns and analytics for Reneo Pharma (RPHM)

- share price and consensus valuation forecast:
Price Performance Chart reneopharma.com|RPHM - Price Target Chart
- stock exchange capitalization data:
Market Valuation Reneo Pharma|RPHM - Enterprise Value
- balance sheet net asset value indicators:
Accounting Value of a Share Reneo Pharmaceuticals|RPHM - Book Capitalization|Market Capitalization to Book Value Ratio reneopharma.com|RPHM - Aggregate Company Assets
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio Reneo Pharmaceuticals|RPHM - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Reneo Pharmaceuticals, Inc|RPHM - Company Aggregate Debts|Debts to Book Capitalization Reneo Pharma|RPHM - Company Long-Term Debt|Company Short-Term Loans and Borrowings Reneo Pharmaceuticals|Immediate Liquidity reneopharma.com
- earnings and valuation multiples information:
RPHM - Company Net Income|Net Profit Forecast Reneo Pharmaceuticals|RPHM - P/E Multiple|Projected Price to Earnings Ratio Reneo Pharmaceuticals Inc.|RPHM - Price/Earnings to Growth Ratio|Company Value to EBITDA Reneo Pharma|RPHM - Operating profit before deduction of amortization|Earnings per share for the trailing year Reneo Pharmaceuticals|RPHM - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months reneopharma.com|RPHM - Earnings growth in current year|Expected earnings per share trend next year Reneo Pharmaceuticals
- issuer revenue and sales details:
RPHM - Revenue and Sales Volume|Projected Sales Volume reneopharma.com|RPHM - Price-to-Revenue Ratio|Forward Price to Sales Reneo Pharma
General company analysis:RPHM reneopharma.com
Finished products of Reneo Pharmaceuticals

The creation of an innovative myopathy therapy ecosystem makes Reneo Pharmaceuticals (RPHM) a high-tech asset, where the price-to-sales ratio reflects market expectations for future breakthroughs. The current value of compares market capitalization with actual sales volume, allowing investors to assess the degree of the stock's overbought status and the risk of correction should the commercialization pace of scientific developments fail to meet projected figures.

Competitors of Reneo Pharmaceuticals

VRTX (vrtx.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Alnylam ALNY|INSM (Insmed Inc.) - Price-to-Sales Ratio|United Therapeutics Corp. - P/S Multiple|Market Capitalization-to-Revenue Ratio BMRN (BioMarin Corp)|BBIO: P/S Multiple|BGM Group (BGM) - P/S Multiple|Price-to-Revenue Ratio Cogent Biosciences, Inc.|XERS: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Keros Pharma (KROS)|Market Cap to Revenue Arcturus Corp ARCT|P/S Multiple ETON (Eton Pharmaceuticals)|P/S Multiple kamada.com KMDA|FULC - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio ABEO (Abeona Therapeutics)|MREO: P/S Multiple|Price to Sales Protalix BioTherapeutics, Inc (PLX)|Price-to-Revenue Ratio Pliant Therapeutics Inc|Market Cap to Revenue Ratio APLT (appliedtherapeutics.com)|P/S Multiple RNTX|GELS - Price to Sales|Price-to-Revenue Ratio Aytu BioPharma AYTU|Chemomab Therapeutics Ltd (CMMB) - Price to Sales|SRXH: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio PLRZ (Polyrizon Ltd)|zentaris.com (AEZS) - Price-to-Revenue Ratio|Price-to-Sales Ratio CYTH (Cyclo Therapeutics Inc.)|INZY (Inozyme Pharma Inc.) - P/S Multiple|CSCI: Market Capitalization-to-Revenue Ratio